darunavir has been researched along with indinavir sulfate in 38 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (indinavir sulfate) | Trials (indinavir sulfate) | Recent Studies (post-2010) (indinavir sulfate) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 1,834 | 328 | 146 |
| Protein | Taxonomy | darunavir (IC50) | indinavir sulfate (IC50) |
|---|---|---|---|
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (BRU ISOLATE) | 0.0004 | |
| Gag polyprotein | HIV-1 M:B_MN | 0.02 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.2 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.0261 | |
| Substance-K receptor | Homo sapiens (human) | 5.101 | |
| Thromboxane-A synthase | Homo sapiens (human) | 1.851 | |
| Protease | Human immunodeficiency virus 1 | 0.0349 | |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | 7.8 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 3.8 | |
| Protease | Human immunodeficiency virus 1 | 0.0044 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (50.00) | 29.6817 |
| 2010's | 16 (42.11) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; Jonckers, TH; King, NM; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Tahri, A; Verschueren, WG; Wigerinck, PB | 1 |
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB | 1 |
| Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX | 1 |
| Boross, PI; Ghosh, AK; Harrison, RW; Kovalevsky, AY; Leshchenko, S; Liu, F; Tie, Y; Wang, YF; Weber, IT | 1 |
| Das, D; Gatanaga, H; Ghosh, AK; Grum-Tokars, V; Hussain, AK; Koh, Y; Kovalevsky, AY; Leshchenko, S; Li, J; Maeda, K; Mitsuya, H; Sridhar, PR; Walters, DE; Weber, IT; Wedekind, JE | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A | 1 |
| Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI | 1 |
| Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B | 1 |
| Brynda, J; Cígler, P; Fanfrlík, J; Grantz Sasková, K; Grüner, B; Konvalinka, J; Kozísek, M; Král, V; Lepsík, M; Plesek, J; Pokorná, J; Rezácová, P; Václavíková, J | 1 |
| Baldridge, A; Gemma, S; Ghosh, AK; Koh, Y; Kovalevsky, AY; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H | 1 |
| Anderson, DD; Baldridge, A; Ghosh, AK; Koh, Y; Leshchenko-Yashchuk, S; Miller, HB; Mitsuya, H; Noetzel, M; Tie, Y; Wang, YF; Weber, IT | 1 |
| Amano, M; Anderson, DD; Baldridge, A; Chumanevich, AA; Ghosh, AK; Hong, L; Koh, Y; Kovalevsky, AY; Kulkarni, S; Mitsuya, H; Tang, J; Tojo, Y; Wang, YF; Weber, IT | 1 |
| Axelsson, L; Ekegren, JK; Hallberg, A; Kihlström, J; Larhed, M; Mahalingam, AK; Samuelsson, B; Unge, T; Wallberg, H; Wannberg, J | 1 |
| Amano, M; Anderson, DD; Aoki, M; Das, D; Ghosh, AK; Koh, Y; Kulkarni, S; Mitsuya, H; Tojo, Y | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Cane, PA; Kolli, M; Myers, RE; Parry, CM; Pillay, D; Schiffer, C | 1 |
| Amano, M; Baldridge, A; Chapsal, BD; Ghosh, AK; Koh, Y; Mitsuya, H; Steffey, MP; Walters, DE | 1 |
| Agniswamy, J; Amano, M; Chapsal, BD; Ghosh, AK; Mitsuya, H; Parham, GL; Steffey, M; Wang, YF; Weber, IT | 1 |
| Agniswamy, J; Amano, M; Ghosh, AK; Martyr, CD; Mitsuya, H; Nyalapatla, PR; Osswald, HL; Parham, GL; Wang, YF; Weber, IT | 1 |
| Bai, XG; Liu, HT; Wang, JX; Wang, YC; Yang, ZH; Zhou, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agniswamy, J; Ghosh, AK; Hattori, SI; Jadhav, RD; Kovela, S; Mitsuya, H; Osswald, H; Simpson, H; Wang, YF; Weber, IT | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Boross, PI; Chen, X; Gaddis, L; Harrison, RW; Liu, F; Tie, Y; Tozser, J; Wang, YF; Weber, IT | 1 |
| Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R | 1 |
| Louis, JM; Sayer, JM | 1 |
| Chandrasekar, S; Jayakanthan, M; Mathur, PP; Muthukumaran, J | 1 |
| Annaert, P; Augustijns, P; Camus, S; Snoeys, J; Van Pelt, J; Ye, ZW | 1 |
| De Marez, T; De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, V; Vangeneugden, T | 1 |
| Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Leonis, G; Papadopoulos, MG; Steinbrecher, T | 1 |
| Hirano, Y; Komatsu, TS; Koyama, YM; Morimoto, G; Ohno, Y; Okimoto, N; Taiji, M | 1 |
2 review(s) available for darunavir and indinavir sulfate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Quality control of protease inhibitors.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides | 2008 |
1 trial(s) available for darunavir and indinavir sulfate
| Article | Year |
|---|---|
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
35 other study(ies) available for darunavir and indinavir sulfate
| Article | Year |
|---|---|
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; Cell Line; Crystallography, X-Ray; Darunavir; Dogs; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Molecular Conformation; Mutation; Rats; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Thermodynamics | 2005 |
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles | 2005 |
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides | 2006 |
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
Topics: Crystallization; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Indinavir; Kinetics; Models, Molecular; Molecular Conformation; Mutation; Sulfonamides | 2006 |
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Molecular Structure; Protein Conformation; Protein Structure, Tertiary; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2006 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication | 2007 |
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Topics: Algorithms; Anti-Retroviral Agents; Benzodioxoles; Blood Proteins; Carbamates; Cell Line; Drug Resistance, Viral; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Orosomucoid; Phenotype; Serum; Serum Albumin; Tyrosine | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage | 2008 |
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides | 2008 |
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Topics: Boron Compounds; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Metals; Models, Molecular; Molecular Structure; Mutation | 2008 |
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Topics: Antiviral Agents; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Ethers, Cyclic; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Ligands; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Polyesters; Stereoisomerism; Structure-Activity Relationship; T-Lymphocytes; Water | 2008 |
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides | 2009 |
Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
Topics: Binding Sites; Crystallography, X-Ray; Drug Design; HIV Protease Inhibitors; Ligands; Oxazolidinones; Protein Binding; Pyrrolidinones; Structure-Activity Relationship | 2009 |
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
Topics: Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Macrocyclic Compounds; Models, Molecular; Molecular Conformation; Mutation | 2009 |
HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Topics: Alcohols; Antiviral Agents; Crystallography, X-Ray; HIV Protease; HIV Protease Inhibitors; HIV-1; Inhibitory Concentration 50; Molecular Mimicry; Mutation, Missense | 2010 |
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Topics: Cell Line; Dimerization; Drug Resistance, Multiple, Viral; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Macrocyclic Compounds; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Virus Replication | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
Topics: Cell Line; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; gag Gene Products, Human Immunodeficiency Virus; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Virus Replication | 2011 |
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
Topics: Carbamates; Catalytic Domain; Cell Line; Crystallography, X-Ray; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Protein Binding; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2011 |
Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.
Topics: Amino Acid Substitution; Binding Sites; Biocatalysis; Cell Line; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Chemical; Models, Molecular; Molecular Structure; Mutation; Protein Binding; Protein Structure, Tertiary; Structure-Activity Relationship; Urethane | 2011 |
Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.
Topics: Crystallography, X-Ray; HIV Protease; HIV Protease Inhibitors; Ligands; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular | 2013 |
Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
Topics: Amines; Dose-Response Relationship, Drug; Drug Discovery; HIV Protease; HIV Protease Inhibitors; HIV-1; Ligands; Molecular Structure; Structure-Activity Relationship | 2015 |
Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.
Topics: Antiviral Agents; Chromans; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; HIV; HIV Protease; HIV Protease Inhibitors; Ligands; Models, Molecular; Molecular Structure; Naphthalenes; Structure-Activity Relationship | 2018 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Topics: Amino Acid Substitution; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; Electrons; HIV Protease; HIV Protease Inhibitors; Humans; Hydrogen Bonding; Indinavir; Kinetics; Models, Molecular; Molecular Conformation; Mutation; Protein Structure, Tertiary; Static Electricity; Substrate Specificity; Sulfonamides | 2005 |
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2009 |
Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Computational Biology; Cytochrome P-450 CYP3A; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Sulfonamides | 2010 |
Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes.
Topics: Animals; Bile Acids and Salts; Biological Transport; Darunavir; Dogs; Dosage Forms; Female; Fluoresceins; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Liver; Male; Middle Aged; Rats; Rats, Wistar; Ritonavir; Species Specificity; Sulfonamides; Sus scrofa | 2010 |
Pharmacokinetic interaction between indinavir and darunavir with low-dose ritonavir in healthy volunteers.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Interactions; Female; Healthy Volunteers; Humans; Indinavir; Male; Plasma; Ritonavir; Sulfonamides; Young Adult | 2010 |
HIV-1 protease mutations and protease inhibitor cross-resistance.
Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides | 2010 |
A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Topics: Anti-HIV Agents; Carbamates; Cluster Analysis; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrogen Bonding; Indinavir; Molecular Dynamics Simulation; Mutation; Protein Conformation; Saquinavir; Sulfonamides; Thermodynamics | 2013 |
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation.
Topics: Betacoronavirus; Binding Sites; Biophysical Phenomena; Catalytic Domain; Computational Biology; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Darunavir; Drug Repositioning; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Dynamics Simulation; Nelfinavir; Pandemics; Pneumonia, Viral; Ritonavir; Saquinavir; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |